IL17A and memory impairment: The probe trial demonstrated significant improvement in the IL-17A−/− + Sev group (Figure 4(a,c)) with respect to the decreases in the number of platform crossings as well as time spent in the target quadrant in the Sev group, indicating the potential attenuation of long-term memory impairments after multiple sevoflurane exposures by IL-17A deletion.